Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

Summary

This study will test the hypothesis that CF101, administered orally, will reduce intraocular pressure in patients with ocular hypertension and/or glaucoma. Eligible patients with elevated intraocular pressure will be evaluated and treated by ophthalmologist investigators, and will receive either CF101 pills or placebo (dummy) pills twice daily for 16 weeks. Ocular pressure, visual fields, and other aspects of safety and effectiveness will be monitored on a regular basis.

Timeline

Start

2010-10

Primary completion

2016-12

Completion

2017-04

Drugs

Indications